Remyelination promoting therapies in multiple sclerosis animal models: a systematic review and meta-analysis.

ABSTRACT: An unmet but urgent medical need is the development of myelin repair promoting therapies for Multiple Sclerosis (MS). Many such therapies have been pre-clinically tested using different models of toxic demyelination such as cuprizone, ethidium bromide, or lysolecithin and some of the therapies already entered clinical trials. However, keeping track on all these possible new therapies and their efficacy has become difficult with the increasing number of studies. In this study, we aimed at summarizing the current evidence on such therapies through a systematic review and at providing an estimate of the effects of tested interventions by a meta-analysis. We show that 88 different therapies have been pre-clinically tested for remyelination. 25 of them (28%) entered clinical trials. Our meta-an

SUBMITTER: Hooijmans CR 

PROVIDER: S-EPMC6351564 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature